Skip to main content
    P

    Pelthos Therapeutics Inc. (PTHS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $7.11
    -0.33 (-4.44%)

    Market Cap: $29.24M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Pelthos Therapeutics Inc. (PTHS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Pelthos Therapeutics reported revenue of $16.80M for the fiscal year ended Dec 31, 2025. That year, net income was -$43.32M with a net margin of -257.9%, operating cash flow was -$22.59M and free cash flow was -$30.59M. The quarter ended Sep 30, 2026 had revenue of $15.39M and net income of -$7.89M.

    Revenue and Margins

    Over the 5 years to Dec 2025, revenue grew from $199.93K, a compound annual rate of 142.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$16.80MN/A76.3%-193.1%-257.9%
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0-100.0%N/AN/AN/A
    Dec 2020$199.93KN/A100.0%-677.2%-330.4%
    Annual, fiscal years ended Dec 2020 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Revenue$16.80M$0$0$0$0$199.93K
    Cost of revenue$3.99M$0$0$0N/AN/A
    Gross profit$12.81M$0$0$0N/A$199.93K
    Research and development$1.23M$1.18M$2.58M$391.73K$209.05K$138.59K
    Operating income-$32.43M-$7.57M-$6.86M-$2.32M-$839.00K-$1.35M
    Net income-$43.32M-$7.96M-$7.38M-$2.46M-$595.39K-$660.58K
    EBITDAN/A-$6.88M-$6.67M-$2.18M-$595.13K-$658.91K
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$15.39M$15.60M$10.91M$9.39M$7.41M$0$0-$3.53K$0$3.53K$0N/A
    Gross profit$13.73M$11.99M$9.23M$7.72M$5.09M$0$0-$3.53K$0$3.53K$0N/A
    Operating income-$9.69M-$17.32M-$13.09M-$12.00M-$15.36M-$3.23M-$1.83M-$1.82M-$2.05M-$1.76M-$1.93M-$3.88M
    Net income-$7.89M-$23.42M-$25.07M-$21.66M-$16.24M-$3.45M-$1.97M-$1.93M-$1.70M-$1.77M-$2.56M-$4.04M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $32.08M exceeded cash and equivalents by $14.10M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Total assets$130.40M$1.37M$96.39K$55.07K$0N/A
    Current assets$53.41M$1.37M$96.39K$55.07K$0N/A
    Cash and equivalents$17.97M$513.00K$96.39K$55.07K$0N/A
    Total liabilities$91.52M$4.08M$6.54M$3.76M$3.68MN/A
    Short-term debt$635.00K$2.19M$750.08K$104.80KN/AN/A
    Long-term debt$31.44M$0N/AN/AN/AN/A
    Shareholder equity$38.88M-$2.71M-$6.44M-$3.71M-$3.68MN/A
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$128.82M$137.36M$145.38M$130.40M$126.43M$822.85K$911.18K$1.37M$2.14M$2.60M$4.03M$96.39K
    Total liabilities$135.00M$138.86M$126.11M$91.52M$68.18M$7.32M$5.11M$4.08M$3.57M$2.79M$2.90M$6.54M
    Cash and equivalents$17.69M$24.19M$31.98M$18.02M$14.20M$59.17K$131.32K$513.44K$1.25M$2.41M$3.77M$96.39K
    Shareholder equity-$6.19M-$1.50M$19.27M$38.88M$58.25M-$6.49M-$4.20M-$2.71M-$1.43M-$182.52K$1.13M-$6.44M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Operating cash flow-$22.59M-$5.79M-$981.03K-$1.57M-$1.59M
    Capital expenditures$8.00M$0$0$0$0
    Free cash flow-$30.59M-$5.79M-$981.03K-$1.57M-$1.59M
    Share repurchases$0$75.00K$0N/AN/A
    Investing cash flow-$5.24M$0$0$0N/A
    Financing cash flow$45.34M$6.21M$1.02M$1.62M$1.59M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$5.16M-$7.66M-$13.13M-$6.25M-$15.26M-$447.00K-$632.00K-$670.00K-$177.69K-$2.95M-$1.99M-$356.81K
    Capital expenditures$60.00K$2.00K$194.00K$99.00K$0$5$0$0$0$0$0$3
    Free cash flow-$5.22M-$7.67M-$13.32M-$6.35M-$15.26M-$447.00K-$632.00K-$670.00K-$177.69K-$2.95M-$1.99M-$356.81K
    Last 12 quarters

    Frequently Asked Questions About PTHS

    What is Pelthos Therapeutics' annual revenue?

    Pelthos Therapeutics reported revenue of $16.80M for the fiscal year ended Dec 31, 2025.

    Is Pelthos Therapeutics profitable?

    No. Pelthos Therapeutics reported net income of -$43.32M for the fiscal year ended Dec 31, 2025, with a net margin of -257.9%.

    How much free cash flow does PTHS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$22.59M minus capital expenditures of $8.00M produced free cash flow of -$30.59M.

    How much debt does Pelthos Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $31.44M, short-term debt of $635.00K and cash and equivalents of $17.97M.

    What is PTHS's profit margin?

    For the fiscal year ended Dec 31, 2025, Pelthos Therapeutics reported gross margin of 76.3%, operating margin of -193.1% and net margin of -257.9%.